Today: 23 May 2026
Hub Group stock price slides after $77 million accounting error triggers restatement, analyst cuts
6 February 2026
2 mins read

Hub Group stock price slides after $77 million accounting error triggers restatement, analyst cuts

New York, February 6, 2026, 15:05 (EST) — Regular session

  • Hub Group shares slumped 18.6% in afternoon trading after the company revealed an accounting error and pushed back its results.
  • The audit committee’s review found that certain quarterly financial statements for 2025 are no longer reliable.
  • Stifel and Baird both downgraded their ratings, with investors still left waiting on a postponed 2025 annual report and new restated figures.

Hub Group Inc (HUBG) tumbled 18.6% to $41.76 on Friday. The logistics firm disclosed an accounting error—now it needs to restate three quarters from 2025 and hold back its full results. Earlier in the session, shares hit a low of $33.00.

In a filing to the SEC, Hub Group’s audit committee determined its unaudited financial statements for the first three quarters of 2025 were materially misstated and should not be relied on. The company also expects to conclude it lacked effective disclosure controls and internal control over financial reporting for 2025, after discussions with Ernst & Young.

Hub Group disclosed in a press release alongside its filing that it had understated purchased transportation costs and accounts payable for the first nine months of 2025, pegging the related amount at $77 million. The company, based in Oak Brook, Illinois, said there’s no expected effect on cash or operating cash flow. Hub Group also delayed its full earnings release and conference call as it addresses the restatement. “Accuracy and transparency in reporting on our performance is of the utmost importance at Hub Group,” Chief Executive Phil Yeager said. SEC

Purchased transportation costs—what freight brokers and logistics players shell out to outside carriers to haul freight—can throw off reported margins and quarterly profits if booked late or misclassified. The cash itself may go out the door on time, but when the numbers don’t line up, investors often see a red flag for trust.

Hub Group released some early numbers alongside its update, projecting full-year 2025 revenue at around $3.7 billion and operating cash flow at $194 million. For 2026, the company said it’s aiming for revenue between $3.65 billion and $3.95 billion, with capex in the range of $35 million to $45 million. Intermodal volume ticked up 1% in the fourth quarter versus the same period last year.

Stifel wasted no time slashing Hub Group to “sell” from “buy” and chopping its price target down to $27 from $52. The firm flagged the accounting problem, warning that margins could be reset lower and pegging 2027 earnings at $1.75 a share. Baird likewise cut its rating to “neutral” from “outperform” and set the target at $29, citing the haze around the year-end audit and pending restatement. Investing.com UK

Hub Group stood out on Friday, falling behind a transport sector that mostly saw gains. The SPDR fund tracking the S&P 500 (SPY) climbed roughly 1.8%, and the iShares U.S. Transportation ETF (IYT) posted a 1.7% rise. Shares of J.B. Hunt (JBHT), C.H. Robinson (CHRW) and XPO (XPO) all moved higher as well.

Now comes the focus on the company’s audited results: Are the adjustments bleeding into the fourth quarter? Which segments take the biggest cost hit? And what’s the fallout for operating margin in the revised periods?

Still, the risk scenario isn’t clear-cut. Hub Group noted it’s evaluating if the problem touches 2023 and 2024 financials. A prolonged review process could keep certain investors wary, particularly if the final restatement expands or if remediation of controls drags on beyond what markets are pricing in.

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms
Previous Story

Molina Healthcare stock dives 27% after 2026 profit outlook reset; Medicare Advantage exit looms

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL
Next Story

Oracle stock rebounds after a bruising week — what traders are watching next for ORCL

Go toTop